JPMorganChase Announces Conference Calls to Review First-Quarter, Second-Quarter, Third-Quarter and Fourth-Quarter 2026 Earnings
NEW YORK, May 21, 2025--(BUSINESS WIRE)--JPMorgan Chase & Co. (NYSE: JPM) ("JPMorganChase" or the "Firm") plans to host conference calls to review financial results on the following dates:
First-quarter 2026 – Tuesday, April 14, 2026 at 8:30 a.m. (Eastern)
Second-quarter 2026 – Tuesday, July 14, 2026 at 8:30 a.m. (Eastern)
Third-quarter 2026 – Tuesday, October 13, 2026 at 8:30 a.m. (Eastern)
Fourth-quarter 2026 – Thursday, January 14, 2027 at 8:30 a.m. (Eastern)
The financial results are scheduled to be released at approximately 6:45 a.m. (Eastern) on the dates noted above, and live audio webcasts and presentation slides will be made available on www.jpmorganchase.com under Investor Relations, Events & Presentations. Dial-in information will be provided at a later date.
JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders' equity as of March 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521854619/en/
Contacts
Investor Contact: Mikael Grubb212-270-2479
Media Contact:Joseph Evangelisti 212-270-7438
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
First Aero-Medical Cessna SkyCourier to be Delivered to Tassili Travail Aérien in Africa, Launching New Era of Medevac Services
PARIS--(BUSINESS WIRE)-- Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced today at the Paris Air Show that Tassili Travail Aérien (TTA) has signed a purchase agreement for two new Cessna SkyCourier aircraft, marking the first order of an aero-medical equipped SkyCourier and the first SkyCourier order in Africa. Tassili Travail Aérien (TTA) has signed a purchase agreement for two new Cessna SkyCourier aircraft, marking the first order of an aero-medical equipped SkyCourier and the first SkyCourier order in Africa. Based in Algeria, TTA is a subsidiary of Sonatrach, the national state-owned oil and gas company. TTA provides passenger transportation, aero-medical evacuation, and other special mission services to the energy sector across Algeria. The Cessna SkyCourier is designed and manufactured by Textron Aviation. 'The Cessna SkyCourier is a versatile aircraft capable of supporting challenging missions, high payloads and short, rough runways worldwide,' said Bob Gibbs, vice president, Special Mission Sales. 'TTA's mission package includes the advanced Lifeport PLUS Powered Medevac System, allowing TTA to quickly switch from passenger or cargo to medevac missions.' The twin-engine, large utility Cessna SkyCourier turboprop will modernize TTA's fleet, offering improved efficiency and reliability, and lower operating costs, while supporting transportation and medevac missions. The aircraft will be based in Algiers and Hassi Messaoud, Algeria, and delivery is anticipated in 2026. Endless Special Missions Possibilities When government, military and commercial customers want airborne solutions for critical missions, they turn to Textron Aviation. The company's aviation solutions provide the high-performance and flight characteristics required to address the unique challenges of special missions operations. With unparalleled quality, versatility and low operating costs, Textron Aviation products are ideal for air ambulance, intelligence, surveillance and reconnaissance (ISR); utility transport, aerial survey, flight inspection; training and many other special operations. About the Cessna SkyCourier The Cessna SkyCourier twin-engine, high-wing turboprop offers a combination of performance and lower operating costs for air freight, commuter and special mission operators. It's available in both freighter and passenger variants, as well as a Combi configuration or with a gravel kit for maximum flexibility. The 19-passenger variant includes separate crew and passenger doors for smooth boarding, a large baggage compartment and large cabin windows for natural light and views. The freighter variant features a flat-floor cabin that is sized to handle up to three LD3 shipping containers with an impressive 6,000 pounds of payload capability. Both variants offer a large cargo door and single-point pressure refueling to enable faster turnarounds. The aircraft is powered by two wing-mounted Pratt & Whitney Canada PT6A-65SC turboprop engines and features the McCauley Propeller C779, a heavy-duty and reliable 110-inch aluminum four-blade propeller, which is full feathering with reversible pitch, designed to enhance the performance of the aircraft while hauling tremendous loads. The SkyCourier is operated with Garmin G1000 NXi avionics and has a maximum cruise speed of more than 200 ktas and a 900 nautical-mile maximum range. About Textron Aviation We inspire the journey of flight. For more than 95 years, Textron Aviation has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops and high-performance pistons, to special missions, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight. For more information, visit | | | About Textron Inc. Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems. For more information, visit: Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, changes in aircraft delivery schedules or cancellations or deferrals of orders.
Business Insider
an hour ago
- Business Insider
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the 'Company'), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'RAPT' with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a reverse stock split-adjusted basis on June 17, 2025. At the effective time of the reverse split, every eight issued and outstanding shares of the Company's common stock will automatically be combined into one issued and outstanding share of the Company's common stock without any change in the par value per share. Fractional shares will not be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to receive a cash payment. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares. The reverse stock split will not affect the absolute number of the Company's authorized shares of common stock, which will remain at 500,000,000, but the total number of authorized shares of the Company's common stock available for future issuance will increase. In addition, proportionate adjustments will be made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding pre-funded warrants and stock options, and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 132.3 million to approximately 16.5 million. RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'will' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the reverse stock split and the timing thereof, the impact of the reverse stock split on stockholders, including any adjustments that may result from the treatment of fractional shares, pre-funded warrant holders and option holders, the potential impact of the reverse stock split on the bid price of the Company's common stock, the expected number of shares of common stock to be issued and outstanding following the reverse stock split, and other statements that are not historical fact. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
Yahoo
3 hours ago
- Yahoo
Is UNH's Dividend at Risk Due to Its Falling Stock Price?
UnitedHealth Group Incorporated (NYSE:UNH) is one of the . UnitedHealth Group Incorporated (NYSE:UNH) is currently facing some challenges in terms of stock price. The stock has fallen sharply, down 39% since the beginning of 2025 and over 37% in the past 12 months. That's a steep drop for such a major company. However, despite the decline, its market value remains strong, keeping it among the world's largest healthcare firms. A senior healthcare professional giving advice to a patient in a clinic. As a result of the lower share price, UnitedHealth Group Incorporated (NYSE:UNH)'s dividend yield has risen to 2.87%. A falling stock price can increase a stock's dividend yield, but that doesn't necessarily mean the dividend is in danger. To judge dividend safety, it's important to look at a company's financials, especially the payout ratio and free cash flow. UnitedHealth Group Incorporated (NYSE:UNH)'s payout ratio stands at a manageable 35%, suggesting it retains enough earnings to reinvest in the business or cushion against downturns. The company also generated $24.9 billion in free cash flow over the past 12 months, while paying just $7.7 billion in dividends. This indicates its dividend remains well-supported as long as business performance stays stable. In addition, UnitedHealth Group Incorporated (NYSE:UNH) has raised its payouts consistently every year since 2011. This makes UNH one of the best next generation dividend aristocrat stocks. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
